Data on HIV/AIDS Reported by Babayemi O. Olakunde and Colleagues (Mobilizing Domestic Funds for the Hiv/aids Response In Nigeria: Estimating the Potential Contribution of the National Health Insurance Scheme): Immune System Diseases and Conditions – HIV/AIDS

2022 DEC 20 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Business Daily -- New research on Immune System Diseases and Conditions - HIV/AIDS is the subject of a report. According to news reporting originating from Abuja, Nigeria, by NewsRx correspondents, research stated, “Amid the dwindling donor support for HIV in Nigeria, there is an urgent need for additional domestic HIV funding. This study estimates the required financial resources for people living with HIV (PLHIV) and the potential magnitude of domestic resources for HIV through the National Health Insurance Scheme (NHIS) and by prioritizing HIV within the health budget.”

Our news editors obtained a quote from the research, “We estimated the resource needs for providing antiretroviral therapy (ART) to adults, children, and pregnant women living with HIV under three scenarios: current coverage rates, coverage rates based on historical trends, and a rapid scale-up situation. We conducted a fiscal space analysis to estimate the potential contribution from macroeconomic growth, the NHIS, and prioritizing HIV within the health budget from 2020 to 2025. At current coverage rates, the annual treatment costs for adults would range between US$ 505 million in 2020 to US$ 655 million in 2025; for children, it ranges from US$ 33.5 million in 2020 to US$ 32 million in 2025. The annual costs of providing PMTCT at current coverage rates range from US$ 65 million in 2020 to US$ 72 million in 2025. An additional US$ 319 million could potentially be generated between 2020 and 2025 through the NHIS for HIV. Prioritizing HIV within the health budget can generate an additional US$ 686 million. Substantial domestic funds can be mobilized by these means to sustain the HIV response.”

According to the news editors, the research concluded: “However, as this additional funding may not be sufficient to cover all PLHIV, a phased approach, initially prioritizing certain populations such as children or pregnant women, is recommended.”

This research has been peer-reviewed.

For more information on this research see: Mobilizing Domestic Funds for the Hiv/aids Response In Nigeria: Estimating the Potential Contribution of the National Health Insurance Scheme. JAIDS Journal of Acquired Immune Deficiency Syndromes, 2022. (Lippincott Williams and Wilkins - www.lww.com; JAIDS Journal of Acquired Immune Deficiency Syndromes - http://journals.lww.com/jaids/pages/default.aspx)

The news editors report that additional information may be obtained by contacting Babayemi O. Olakunde, National Agency for the Control of AIDS, Abuja, Nigeria. Additional authors for this research include Tolulope T. Oladele, Wenhui Mao, Edward Adekola Oladele, Alex Ogundipe, Gavin Yamey and Osondu Ogbuoji.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1097/qai.0000000000003136. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

(Our reports deliver fact-based news of research and discoveries from around the world.)